Viral structural proteins as targets for antivirals

Area of Science:

• Virology
• Drug Discovery
• Structural Biology

Background:

• Viral structural proteins, particularly the capsid, are crucial for viral lifecycle events like assembly and disassembly.
• The precise timing and environmental conditions of these capsid functions make them vulnerable to small molecule interference.
• Previous research has shown success in targeting viral capsids with small molecules in viruses such as rhinovirus, HIV, and Hepatitis B virus.

Purpose of the Study:

• To explore the potential of viral structural proteins as targets for novel antiviral therapies.
• To identify common mechanisms of action among different classes of antiviral molecules targeting viral capsids.
• To investigate how small molecule interference can disrupt essential viral capsid functions.

Main Methods:

• Review of existing literature on antivirals targeting viral structural proteins.
• Analysis of the mechanisms of action for compounds like pleconaril (rhinovirus), bevirimat (HIV), and core protein allosteric modulators (CpAMs) (Hepatitis B virus).
• Comparative analysis of how these different antivirals interact with viral protein structures.

Main Results:

• Compounds targeting viral capsids have shown preliminary success against rhinovirus, poliovirus, HIV, and Hepatitis B virus.
• Antivirals function by interfering with capsid assembly, disassembly, or maturation processes.
• A common mechanism observed is the stabilization of protein-protein interactions within the viral capsid.

Conclusions:

• Stabilizing protein-protein interactions within viral capsids is a promising and common strategy for developing broad-spectrum antivirals.
• Targeting viral structural proteins offers a viable approach for new antiviral drug discovery.
• Understanding these common mechanisms can guide the development of next-generation antiviral therapies.